Article

Brain-Restricted mTOR Inhibition with Binary Pharmacology

2020-11-20

Abstract excerpt

<title>Abstract</title> <p>On-target-off-tissue drug engagement is an important source of adverse effects that constrains the therapeutic window of drug candidates. In diseases of the central nervous system, drugs with brain-restricted pharmacology are highly desirable. Here we report a strategy to achieve inhibition of mTOR while sparing mTOR activity elsewhere through the use of a brain-permeable mTOR inhibitor...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 850056ad-3bda-564d-a1c6-e39ee2a5f8eb
DOI: 10.21203/rs.3.rs-92256/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Brain-Restricted mTOR Inhibition with Binary PharmacologyDOI 10.21203/rs.3.rs-92256/v1Read

Brain-Restricted mTOR Inhibition with Binary PharmacologySemantic proximity Read

Drug discovery targeting the mTOR pathwaySemantic proximity Read

DYRK1A Kinase Inhibitors with Emphasis on CancerSemantic proximity Read

A New Challenging and Promising Era of Tyrosine Kinase InhibitorsSemantic proximity Read

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1Semantic proximity Read

Pharmacological PP2A reactivation overcomes multikinase inhibitor tolerance across brain tumor cell modelsSemantic proximity Read

Tissue-Restricted Inhibition of mTOR Using Chemical GeneticsSemantic proximity Read

Overcoming mTOR resistance mutations with a new-generation mTOR inhibitor.Semantic proximity Read

Identification of a Non-Gatekeeper Hot Spot for Drug-Resistant Mutations in mTOR Kinase.Semantic proximity Read

Beyond Base Camp: Promise and Pitfalls of PI3K/mTOR Inhibition in Pediatric High- Grade GliomasSemantic proximity Read

Inhibition of mTOR-kinase destabilizes MYCN and is a potential therapy for MYCN-dependent tumorsSemantic proximity Read

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapySemantic proximity Read